Use of 13-valent pneumococcal conjugate vaccine and 23-valent
pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP).
NVT, nonvaccine type serotype cases; PPV23-13, 23-valent
pneumococcal polysaccharide vaccine serotype cases excluding those also contained in the 13-valent pneumococcal conjugate vaccine.
Alpers, "Maternal immunization with
pneumococcal polysaccharide vaccine in the highlands of Papua New Guinea," Vaccine, vol.
Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in HIV-infected adults previously vaccinated with
pneumococcal polysaccharide vaccine. J Infect Dis.
The currently available
pneumococcal polysaccharide vaccine, is manufactured by both Merck (Pneumovax 23) and Lederie Laboratories (Pnu-Immune 23), and includes 23 purified capsular polysaccharide antigens (serotypes 1 ,2,3,4,5,6B,7F,8,9N,9V,10A,11A,12F,14 , 15B,17F,18C,19A,19F,20,22F,23F and 33F).
A single dose is required every year for seasonal influenza while a single dose of the
pneumococcal polysaccharide vaccine is needed every five years.
(5,6) The 23-valent
pneumococcal polysaccharide vaccine provides coverage of 74.3% of the strains encountered in this study.
The number one way to protect yourself from pneumonia is to get vaccinated via an influenza shot and a one-time (after age 65)
pneumococcal polysaccharide vaccine (PPV) shot.
Pneumococcal polysaccharide vaccine in young adults and older bronchitics: determination of IgG responses by ELISA and the effect of absorption of serum with non-type specific cell wall polysaccharide.
The new adult recommendation is for persons who are 65 years or older to receive one dose of the
pneumococcal polysaccharide vaccine. Revaccination with
pneumococcal polysaccharide vaccine is indicated after 5 years for certain medical conditions (ACIP, 2003).
* Those who have chronic illness associated with pneumococcal disease should receive the
pneumococcal polysaccharide vaccine.
"Persons greater than or equal to 65 years old and all adults with medical conditions that place them at risk for pneumococcal disease or serious complications of influenza should receive one dose of
pneumococcal polysaccharide vaccine and annual injections of influenza vaccine." 3.